KYOWA KIRIN CO., LTD.

AstraZeneca's Fasenra approved in the US for EGPA, based on MANDARA trial results showing comparable remission rates to mepolizumab and higher OCS tapering success.

AstraZeneca's FASENRA® (benralizumab) approved in the US for treating adult patients with eosinophilic granulomatosis with polyangiitis (EGPA). Approval based on MANDARA Phase III trial results, showing FASENRA's efficacy and safety comparable to mepolizumab. FASENRA helps patients achieve remission and taper off oral corticosteroids.

Fasenra approved in the US for eosinophilic granulomatosis with polyangiitis; MANDARA trial showed nearly 60% of patients achieved remission and 41% fully stopped taking oral corticosteroids.